Research progress on innovative drugs for diabetic nephropathy with potential anti-inflammatory targets
10.12206/j.issn.2097-2024.202109068
- VernacularTitle:以抗炎为潜在靶点的治疗糖尿病肾病的新药研究进展
- Author:
Xiaofei SHI
1
;
Yi CHEN
1
;
Kefa XIANG
1
;
Huimin ZHANG
1
;
Yue GAO
1
;
Xia LIU
1
Author Information
1. a. School of pharmacy, b. Clinical Reaearch Center of the First Affiliated Hospital, Naval Medical University, Shanghai 200433, China.
- Keywords:
diabetic nephropathy;
inflammation;
treatment
- From:
Journal of Pharmaceutical Practice
2023;41(10):581-585
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic nephropathy (DN) is a common microvascular complication of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM)，which is also the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). However, the treatment methods are limited at present. More and more evidences have indicated that inflammatory response is involved in the pathogenesis and progression of DN. Several anti-inflammatory strategies that target specific inflammatory mediators (transcription factors, pro-inflammatory cytokines, chemokines, adhesion molecules) and intracellular signaling pathways have shown benefits in the DN rodent model. The mechanisms related to inflammation in the development and progression of DN were summarized and new strategies to prevent or treat DN based on inflammation were briefly discussed in this review.
